Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Market Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast To 2014 – 2021 Type 2 Diabetes mellitus (T2DM) is a disease marked by lack of insulin, insulin resistance, and high blood sugar. This disease has long-term damage that results in failure and dysfunction of multiple organs including blood vessels, heart, nerves, kidneys, and eyes. About 85% of diabetics have the chances of getting T2DM. The rising cases of diabetes can be attributed to reduced physical activity and consumption of high-calorie diets. A healthy diet and lifestyle change can improve the chances of recovering from T2DM. The T2DM therapeutics market in Asia Pacific has evolved in the last decade. It has brought about promising treatments such as SGLT-2 inhibitor, GLP-1 receptor agonist, DPP-4 inhibitor, sulfonylureas, biguanide, and other insulin therapies. But alternative products offering better glycemic control hamper market growth. GIP (Gastric inhibitory polypeptide) is impaired during type 2 diabetes, but GLP-1 is preserved proving beneficial to therapy. Sulfonylureas help your body secrete more insulin. Examples of medication in this class of medicines are glipizide and glyburide. Meglitinides work similarly to sulfonylureas but are faster-acting agents. Examples of medication include nateglinide and repaglinide. DPP-4 inhibitors reduce blood sugar levels and negate the possibility of weight gain. Examples include saxagliptin and sitagliptin. For further information on this report, please visit http://www.radiantinsights.com/research/type-2-diabetes-mellitus-therapeutics-in-asiapacific-markets GLP-1 receptor agonists lower blood sugar level and slow digestion. Examples of this medication are liraglutide and exenatide. SGLT-2 inhibitors are newest drugs in the market which prevents sugar to be absorbed into the blood and excretes it through the urine. Bariatric surgery is an option for obese patients suffering from T2DM. The T2DM therapeutics market in Asia Pacific is projected to reach about 10.2 billion by 2021, growing at a 7.7% CAGR from 2014 to 2021. It was previously estimated to be worth USD 6 billion in 2013. With over 500 active drugs in the pipeline, many drug-testing candidates are evaluated and given advanced drugs and insulin therapies. In an analysis of clinical trials, T2DM molecules had a failure rate of over 50% in Phase II, with an attrition rate of 86%. The T2DM therapeutics market covers the areas of China, India, Australia, and Japan in Asia Pacific. Notable players of the T2DM therapeutics market are AbbVie, Intarcia Therapeutics, Emisphere, Janssen, and Halozyme Therapeutics. Table Of Content:
1 Table of Contents 4 1.1 List of Tables 6 1.2 List of Figures 7 2 Introduction 9 2.1 Disease Overview 9 2.2 Classification 9 2.3 Symptoms 10 2.4 Etiology 10 2.5 Pathophysiology 11 2.6 Epidemiology 13 2.7 Prognosis 13 2.8 Co-morbidities and Complications 14 2.9 Diagnosis 15 2.10 Assessing Treatment Effectiveness 17 2.11 Treatment 17 2.11.1 Non-insulin T2DM Therapies 19 2.11.2 Insulin T2DM Therapies 22 2.12 Treatment Segments 24 2.12.1 Non-insulin therapies 24 2.12.2 Insulin Therapies 39 Browse All Reports of This Category @ http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare 3 Marketed Products 43 3.1 Overview 43 3.2 Biguanides 44 3.2.1 Metformin 44 3.3 Sulfonylureas 45 3.4 Thiazolidinediones 47 3.4.1 Pioglitazone 47 3.5 GLP-1 receptor agonists 48 3.5.1 Byetta (exenatide) 48 3.5.2 Bydureon (exenatide) 49 3.5.3 Victoza (liraglutide) 50 3.5.4 Lyxumia (lixisenatide) 51 3.5.5 Tanzeum (albiglutide) 53 3.5.6 Trulicity (dulaglutide) 54 3.6 DPP-4 Inhibitors 55 3.6.1 Januvia/Glactiv (sitagliptin) 55 3.6.2 Galvus (vildagliptin) 56
3.6.3 Onglyza (saxagliptin) 57 3.6.4 Trazenta (linagliptin) 58 3.6.5 Zafatek (trelagliptin succinate) 59 3.6.6 Marizev (omarigliptin) 60 3.7 SGLT-2 Inhibitors 61 3.7.1 Forxiga (dapagliflozin) 61 3.7.2 Invokana (canagliflozin) 62 3.7.3 Jardiance (empagliflozin) 63 3.8 Insulin Therapies 63 3.8.1 Lantus (insulin glargine) 63 3.8.2 Levemir (insulin detemir) 64 3.8.3 Tresiba (insulin degludec) 65 3.8.4 Toujeo/ Lantus XR (insulin glargine) 66 3.9 Marketed Products Heat Maps 67 4 Pipeline 70 4.1 Overview 70 4.2 Pipeline Distribution by Stage of Development, Molecule Type and Program Type 71 4.3 Pipeline Distribution by Molecular Target 72 4.4 Clinical Trial Landscape 79 4.4.1 Clinical Trial Failure Rates 79 4.4.2 Clinical Trial Duration 84 4.4.3 Clinical Trial Size 87 4.4.4 Clinical Trial Metrics Analysis 90 4.5 Promising Pipeline Molecules 92 4.5.1 NN-9535 (subcutaneous semaglutide) and OG-217SC (oral semaglutide) - Novo Nordisk 92 4.5.2 ITCA 650 - Intarcia Therapeutics 94 4.5.3 Ertugliflozin - Pfizer 96 4.6 Pipeline Products Heat Map 98 Request Free Sample Of This Study @ http://www.radiantinsights.com/research/type-2diabetes-mellitus-therapeutics-in-asia-pacific-markets#tabs-4 5 Market Forecast to 2021 99 5.1 Geographical Markets 99 5.2 Asia-Pacific Markets 99 5.3 China 102 5.3.1 Treatment Usage Patterns 102 5.3.2 Annual Cost of Therapy 103 5.3.3 Market Size 103 5.4 India 104 5.4.1 Treatment Usage Patterns 104
5.4.2 Annual Cost of Therapy 105 5.4.3 Market Size 106 5.5 Australia 107 5.5.1 Treatment Usage Patterns 107 5.5.2 Annual Cost of Therapy 107 5.5.3 Market Size 108 5.6 Japan 109 5.6.1 Treatment Usage Patterns 109 5.6.2 Annual Cost of Therapy 109 5.6.3 Market Size 110 5.7 Drivers and Barriers for the T2DM Therapeutics Market 111 5.7.1 Drivers 111 5.7.2 Barriers 112 6 Strategic Consolidations 113 6.1 Licensing Deals 113 6.1.1 AbbVie Collaborates with Halozyme Therapeutics to Bank on its ENHANZE Technology 119 6.1.2 Janssen Collaborates with Halozyme Therapeutics to Bank on its ENHANZE Technology 119 6.1.3 Emisphere Signs Licensing Agreement with Novo Nordisk to Develop Oral Formulations Targeting Metabolic Indications 119 6.1.4 Amunix Announces Exclusive Agreements with Naia to Develop GLP-1 and GLP-2 XTEN Products 120 To Get More Details @ http://www.radiantinsights.com/research/type-2-diabetes-mellitustherapeutics-in-asia-pacific-markets 6.2 Co-development Deals 120 6.2.1 Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 (DUROS delivery exenatide) 126 6.2.2 Merck Enters into Co-Development Agreement with Pfizer for ertugliflozin 127 6.2.3 AstraZeneca Enters into Research Agreement with Inserm 127 6.2.4 Intarcia Therapeutics Enters into Co-Development Agreement with Numab 127 6.2.5 AstraZeneca Enters into Co-development Agreement with Bristol-Myers Squibb 128 7 Appendix 129 7.1 All Pipeline Drugs by Phase of Development 129 7.1.1 Discovery 129 7.1.2 Preclinical 132 7.1.3 IND/CTA-filed 140 7.1.4 Phase I 141 7.1.5 Phase II 143
7.1.6 Phase III 145 7.1.7 Pre-registration 145 7.2 Market Forecasts to 2021 146 7.2.1 Asia-Pacific 146 7.2.2 China 146 7.2.3 India 146 7.2.4 Australia 147 7.2.5 Japan 147 7.3 References 148 7.4 Abbreviations 160 7.5 Research Methodology 162 7.5.1 Secondary Research 162 7.5.2 Marketed Product Profiles 163 7.5.3 Late-Stage Pipeline Candidates 163 7.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 163 7.5.5 Forecasting Model 164 7.5.6 Deals Data Analysis 165 7.6 Contact Us 165 7.7 Disclaimer 166 About Us Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of Ancillary services such as, research partnerships/ tie-ups and customized research solutions. Media Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Website: Radiant Insights Visit Our Blog: radiantri.blogspot.com